Auris Medical Holding AG  

(Public, NASDAQ:EARS)   Watch this stock  
Find more results for NYSE:ears
-0.004 (-1.27%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.28 - 0.30
52 week 0.25 - 1.06
Open 0.30
Vol / Avg. 0.00/945,773.00
Mkt cap 13.24M
P/E     -
Div/yield     -
EPS -0.68
Shares 61.17M
Beta 0.11
Inst. own 20%
Mar 12, 2018
Auris Medical Holding AG Extraordinary Shareholders Meeting - 3:30AM EDT - Add to calendar
Jan 4, 2018
Auris Medical Holding AG - Special Call - Webcast
Nov 28, 2017
Q3 2017 Auris Medical Holding AG Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -92.77% -69.32%
Return on average equity -991.86% -104.14%
Employees 22 -
CDP Score - -


Bahnhofstrasse 21
ZUG, ZUG 6300
+41-41-7297194 (Phone)
+41-61-2011351 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).

Officers and directors

Thomas Meyer Chairman of the Board, Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Hernan Levett Chief Financial Officer
Bio & Compensation  - Reuters
Anne Sabine Zoller General Counsel
Age: 36
Bio & Compensation  - Reuters
Cindy McGee Head of Investor Relations and Corporate Communications
Bio & Compensation  - Reuters
Andrea Braun Head of Regulatory and Quality Affairs
Bio & Compensation  - Reuters
Thomas Jung M.D., Ph.D. Chief Development Officer
Bio & Compensation  - Reuters
Bettina Mirella Stubinski Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
James I. Healy M.D. Ph.D. Non-Executive Independent Vice Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
Mats Peter Blom Director
Age: 53
Bio & Compensation  - Reuters
Alain Munoz Ph.D. Director
Age: 69
Bio & Compensation  - Reuters